KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $6.0 billion.

  • Pfizer's Operating Expenses fell 222.58% to $6.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $17.8 billion, marking a year-over-year decrease of 4056.18%. This contributed to the annual value of $28.0 billion for FY2024, which is 148.63% down from last year.
  • As of Q3 2025, Pfizer's Operating Expenses stood at $6.0 billion, which was down 222.58% from $5.8 billion recorded in Q2 2025.
  • In the past 5 years, Pfizer's Operating Expenses registered a high of $10.0 billion during Q4 2023, and its lowest value of $4.8 billion during Q2 2021.
  • Moreover, its 5-year median value for Operating Expenses was $6.1 billion (2022), whereas its average is $6.2 billion.
  • As far as peak fluctuations go, Pfizer's Operating Expenses surged by 2570.16% in 2021, and later plummeted by 2405.11% in 2025.
  • Over the past 5 years, Pfizer's Operating Expenses (Quarter) stood at $6.2 billion in 2021, then rose by 0.96% to $6.3 billion in 2022, then soared by 58.38% to $10.0 billion in 2023, then crashed by 38.18% to $6.2 billion in 2024, then dropped by 2.23% to $6.0 billion in 2025.
  • Its Operating Expenses stands at $6.0 billion for Q3 2025, versus $5.8 billion for Q2 2025 and $5.9 billion for Q1 2025.